Adoption of Artificial Intelligence in Health Care

Original Title: Adoption of Artificial Intelligence in the Health Care Sector

Journal: JAMA health forum

DOI: 10.1001/jamahealthforum.2025.5029

Overview

This study investigated the adoption of artificial intelligence (AI) in the US health care sector compared to other industries from September 2023 to May 2025. Using data from the US Census Bureau's Business Trends and Outlook Survey, which included responses from about 119,300 health care firms, the researchers analyzed biweekly trends in AI use. They found that while AI adoption in health care is increasing, it remains lower than in other sectors. In 2025, 8.3% of health care firms reported using AI, compared to 23.2% in information services and 19.2% in professional, scientific, and technical services. The mean AI use in health care over the study period was 5.9%. A key finding was the identification of an acceleration point in adoption around late December 2024 and early January 2025. Before this point, the biweekly growth rate was minimal at 0.005%; afterward, it increased significantly to 0.03%, representing a 481.5% change in the slope. Within health care, outpatient and ambulatory care firms showed the most substantial growth, increasing from 4.6% adoption in 2023 to 8.7% in 2025, while nursing and residential care facilities saw more limited growth from 3.1% to 4.5%.

Novelty

The study's novelty lies in its use of near real-time, large-scale national survey data to provide a dynamic and comparative view of AI adoption. Unlike previous research that often focused on well-resourced hospitals or specific AI applications, this analysis includes a broad range of organizations of varying sizes across multiple economic sectors. This approach offers a more grounded estimate of AI integration into routine business operations. Furthermore, the application of an interrupted time series analysis to identify a specific inflection point where the rate of adoption accelerated is a distinct contribution. This quantitative evidence of a shift from a nearly flat to a gradually increasing adoption slope provides a data-driven timeline of AI's expanding footprint in the health care industry.

Potential Clinical / Research Applications

The findings have direct implications for future research and policy. Researchers should now investigate the specific types of AI being adopted and the factors driving the disparity between outpatient clinics and residential care facilities. Studies are needed to assess the impact of this rising AI use on clinical outcomes, workforce productivity, and health care costs. It is also important to explore the barriers preventing wider adoption in settings like nursing homes. For policymakers and health care administrators, this study underscores the urgent need for governance frameworks to ensure AI is deployed safely and ethically. It also points to the necessity of developing targeted support programs and financial incentives to help under-resourced subsectors adopt beneficial AI technologies, thereby preventing a widening of care quality gaps. Furthermore, the accelerating trend calls for the proactive development of training curricula for the current and future health care workforce.

Similar Posts

  • A study of 691 FDA-cleared AI/ML devices reveals significant reporting gaps in efficacy, safety, and bias, calling for better regulation.

    Original Title: Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence-Enabled Medical Devices Journal: JAMA health forum DOI: 10.1001/jamahealthforum.2025.3351 FDA AI/ML Device Reporting Lacks Transparency Overview A comprehensive analysis of 691 artificial intelligence and machine learning (AI/ML) medical devices cleared by the US Food and Drug Administration (FDA) between 1995 and 2023 reveals significant deficiencies in benefit-risk reporting. The cross-sectional study examined FDA decision summaries and postmarket surveillance databases. It found that crucial information was frequently missing. For instance, 95.5% of device summaries lacked demographic data for the populations on which the AI was tested, 53.3% did not report the training sample size, and 46.7% omitted the study design. The evidence supporting clearance…

  • Expert Consensus on Sonazoid CEUS for Liver Lesions

    Original Title: Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS) Journal: International journal of surgery (London, England) DOI: 10.1097/JS9.0000000000003510 Overview This document presents an expert consensus on the clinical use of Sonazoid contrast-enhanced ultrasound for managing focal liver lesions. Sonazoid is a second-generation agent that functions as both a blood pool and a Kupffer-cell agent, with a phagocytic rate of 99 percent. Unlike pure blood-pool agents, it provides a stable post-vascular phase that lasts for approximately sixty minutes, enabling thorough liver scans. The consensus covers surveillance, diagnosis of hepatocellular carcinoma, detection of metastases, and interventional guidance. In high-risk patients, Sonazoid improves the detection of…

  • Volumetric Brain Matter Changes in Mild Cognitive Impairment

    Original Title: Biomarkers Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association DOI: 10.1002/alz70856_106355 Overview Mild cognitive impairment (MCI) serves as a critical transitional stage between the typical cognitive changes of aging and the onset of Alzheimer's disease. This study explores structural brain alterations associated with this condition by quantifying gray matter and white matter volumes using high-resolution T1-weighted magnetic resonance imaging. The research team utilized a specialized deep neural network named Vb-Net to perform automated segmentation and volumetric analysis on healthy controls and individuals with MCI. Patients with MCI experienced a 4.60% reduction in gray matter volume and a 5.60% decrease in white matter volume compared to…

  • WeChat-Based AI Agent for Postoperative Orthopedic Care

    Original Title: A randomized controlled trial of a WeChat-based artificial intelligence agent for postoperative care in orthopedic patients Journal: NPJ digital medicine DOI: 10.1038/s41746-025-02269-8 Overview This randomized controlled trial evaluated a GPT-4-powered artificial intelligence agent delivered via the WeChat platform to support postoperative recovery in orthopedic patients. The study included 261 participants, with 140 assigned to the AI-driven intervention and 121 to traditional physician-led communication. Effective postoperative management is often hindered by limited access to timely support and poor adherence to rehabilitation protocols. The AI system demonstrated a significantly faster response time of 0.5 ± 0.6 minutes compared to 358 ± 47.5 minutes in the doctor-led group (p < 0.05)….

  • Multimodal AI for Predicting IVF Pregnancy Outcomes

    Original Title: Multimodal intelligent prediction model for in vitro fertilization Journal: NPJ digital medicine DOI: 10.1038/s41746-025-02331-5 Overview This study introduces VaTEP, a multimodal deep learning framework that integrates time-lapse system videos of developing embryos with tabular clinical data. Developed and validated using data from 9,786 participants across three medical centers, VaTEP predicts three clinical outcomes: fetal heartbeat presence, singleton versus multiple pregnancy, and miscarriage versus live birth. Using a multi-task learning approach, the system optimizes these predictions simultaneously. Results show the model achieved an area under the curve (AUC) of 0.8000 for fetal heartbeat, 0.8823 for singleton versus multiple pregnancy, and 0.9258 for live birth versus miscarriage. These values exceeded…

  • KT-LLM: An Auditable Framework for Kidney Transplant Care

    Original Title: KT-LLM: an evidence-grounded and sequence text framework for auditable kidney transplant modeling Journal: NPJ digital medicine DOI: 10.1038/s41746-025-02323-5 Overview The management of kidney transplantation involves complex longitudinal data and strict regulatory policies that are often difficult to align. This study presents KT-LLM, a framework designed to bridge the gap between structured patient follow-up data and the textual rules governing clinical practice. The system uses a modular architecture consisting of three specialized agents coordinated by a large language model. Agent-A, utilizing a Mamba-based sequence model, predicts survival and graft loss outcomes. Agent-B identifies distinct patient subgroups through deep embedded clustering, while Agent-C translates policy documents into executable rules to…

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA